Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

BDTX Purchases of Investments

Cash used to buy marketable securities and other investments.

Black Diamond Therapeutics, Inc.NASDAQ: BDTX

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments turns positive

Q1 FY2026 purchases of investments was $0, compared with -$23.47M a year earlier. Trailing-twelve-month purchases of investments was -$140.56M. Over 3 fiscal years it compounded at +39.7% a year.

Context

  • Purchases of investments amounted to 234.3% of revenue in FY2025.
  • Purchases of investments grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly purchases of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$35.14M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$164.03M+33.5% YoY
LTMMar 2026
-$140.56M+49.4% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+33.5%——
3-year CAGR+39.7%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(164.03M) USD
Year-over-year change
-33.5%

Purchases of Investments vs competitors

How BDTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +49.4% is the 3rd highest of 7, against a peer median of -18.4%.
  • Over three fiscal years its annual growth of +39.7% compares with a peer median of +13.9%.
BDTX Competitors
Purchases of Investments for BDTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$345.19M USD+129.9%+6.9%498.7%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$176.99M USD+0.4%+38.2%1217.3%
IMRXImmuneering CorporationLTM Mar 2026$160.59M USD—+20.9%—
CRBUCaribou Biosciences, Inc.LTM Mar 2026$156.06M USD-37.3%-23.7%1393.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$147.06M USD-47.7%-31.6%521.0%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$140.56M USD+49.4%+39.7%—
IVAInventiva S.A.FY2025€127.69M EUR—+4935.6%2848.4%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$113.72M USD——192745.8%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$4.95M USD-96.0%——
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$0 USD——0.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
Peer median (excluding BDTX) —-18.4%+13.9%869.2%

Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Depreciation & Amortization205K508K437K343K325K
Deferred Income Tax2.18M0000
Stock-Based Compensation14.04M12.2M9.6M10.63M6.63M
Change in Working Capital7.02M(9.9M)3.69M(2.69M)(8.73M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.57M(2.23M)597K1.68M(3.43M)
Other Working Capital5.45M(7.67M)3.09M(4.38M)(5.3M)
Other Non-Cash Items2.01M3.28M2M(905K)9.02M
Operating Cash Flow(100.15M)(85.08M)(66.72M)(62.3M)29.61M
Capital Expenditures(2.71M)(192K)(33K)00
Acquisitions (Net)2.7M9K094K27K
Purchases of Investments(49.51M)(60.14M)(61.89M)(122.88M)(164.03M)
Sales of Investments182.83M113.69M78.17M139.75M119.02M
Other Investing Activities(2.7M)095K074K
Investing Cash Flow130.61M53.37M16.35M16.97M(44.91M)
Debt Repayment00000
Common Stock Issued729K177K71.85M24.49M(146K)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0082K1.05M0
Financing Cash Flow729K177K71.93M25.55M(146K)
Effect of Forex Changes00000
Net Change in Cash31.19M(31.54M)21.56M(19.79M)(15.44M)
Free Cash Flow(102.86M)(85.27M)(66.75M)(62.3M)29.61M

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Intrinsic Alpha fair value

Locked

Current Price

$1.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.